**Core Concept:** Brachytherapy is a type of radiotherapy that uses radioactive sources placed directly within, adjacent to, or near the tissue being treated. The purpose is to deliver high radiation doses to the target while minimizing exposure to surrounding healthy tissues. Radioactive isotopes used in brachytherapy include various types and strengths.

**Why the Correct Answer is Right:** Radioactive isotopes used for brachytherapy are typically short-lived, emitting ionizing radiation (gamma rays or beta particles) to damage tumor cells and inhibit their growth. The correct answer, **D, refers to I-125 (Iodine-125)**, which is a beta-emitting radioactive isotope with a half-life of 59.4 days. This short half-life ensures that the radiation dose remains high within the target tissue while decreasing rapidly over time, reducing exposure to surrounding healthy tissues.

**Why Each Wrong Option is Incorrect:**

A. **I-131 (Iodine-131)** is also a beta-emitting radioactive isotope, but its half-life (8 days) is too short for brachytherapy purposes, as it would rapidly lose radiation intensity within the target area.

B. **Cobalt-60 (Co-60)** is a gamma-emitting radioactive isotope with a half-life of 5.27 years. This long half-life makes Co-60 unsuitable for brachytherapy, as it would take too long for the radiation dose to decrease within the target tissue and remain high enough to effectively treat the tumor.

C. **Strontium-90 (Sr-90)** is a beta-emitting radioactive isotope, but its half-life (29 years) is excessively long for brachytherapy, as it would take too long for the radiation dose to decrease within the target area, potentially causing unnecessary tissue damage to surrounding healthy tissues.

**Clinical Pearls:**

1. **Long half-life radioactive isotopes are unsuitable for brachytherapy as they do not decay fast enough within the target tissue.**
2. **Short half-life radioactive isotopes are also unsuitable for brachytherapy as they decay too quickly within the target tissue.**
3. **Choosing the appropriate radioactive isotope depends on the desired balance between the rate of decay within the target tissue and the duration of the radiation exposure.**

**Correct Answer Explanation:**

**Correct Answer: D (Iodine-125, half-life: 59.8 days)**

Iodine-125 is a suitable radioactive isotope for brachytherapy because it has a half-life of 59.8 days that allows for an adequate decay within the target tissue, and the radiation exposure duration.